Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPain ManagementAetna Pulsed Radiofrequency Coverage Update | Open…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0735

    Pulsed Radiofrequency

    Customize your policy alerts

    Sign up for Aetna Policy 0735 alerts

    Get alerted when Policy 0735 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This clinical policy bulletin addresses the coverage stance and coding guidance for pulsed radiofrequency procedures and related modalities for Aetna members.

    Policy Summary
    PayerAetna
    PolicyPulsed Radiofrequency
    Policy CodePolicy 0735
    Change TypeNo material change
    Effective DateAug 21, 2007
    Last ReviewSep 20, 2023
    Next Review DateAug 8, 2024
    Key ActionObtain prior authorization and document failure of conservative therapies and diagnostic block responses when requesting pulsed radiofrequency.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    71indications experimental
    2modalities experimental
    6RCTs cited
    reportedno serious complications
    09/20/2023last review

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria — Pulsed Radiofrequency

    inv-01: Experimental and Investigational — Aetna considers pulsed radiofrequency experimental and investigational for all indications, including the enumerated list

    Aetna considers pulsed radiofrequency experimental and investigational for all indications listed below because effectiveness has not been established.

    PRF experimental indications list: Pulsed radiofrequency (PRF) is considered experimental and investigational for the listed indications (items 1–71).

    See source for full enumerated list

    inv-02: Modalities - Experimental/Investigational — specific PRF modalities considered unestablished

    The following specific PRF modalities are considered experimental and investigational because effectiveness has not been established.

    Specific modalities: Stimpod NMS460 nerve stimulator (Xavant Technology) and a wearable pulsed radiofrequency therapy device for post‑amputation pain are experimental and investigational.

    inv-03: Covered with conditions — selective indications supported by limited evidence

    Selected scenarios in the literature where limited evidence suggests PRF may provide benefit in carefully selected patients:

    Cervical radicular pain (select patients): PRF of the cervical dorsal root ganglion demonstrated improved global perceived effect and VAS at 3 months in a randomized double‑blind trial in carefully selected patients.

    Careful patient selection and further research recommended.

    Occipital neuralgia with positive diagnostic block: Prospective studies applying PRF to greater/lesser occipital nerves after a positive diagnostic block reported significant reductions in pain and medication use up to 6 months.

    Diagnostic nerve block was an inclusion criterion in reported studies.

    Lumbosacral radicular syndrome (select patients): Observational studies and audits report short‑term benefit in a subset of patients; clinical audit reported ≥50% pain relief for ≥2 months in ~29.5% of interventions.

    Results variable; randomized trials needed.

    Peripheral nerve or localized syndromes (limited evidence): Case series and small studies (for example: spermatic cord denervation for orchialgia, ilio‑inguinal/genitofemoral nerve PRF for post‑surgical orchialgia, myofascial inter‑fascial PRF) report mixed short‑term results and are considered limited evidence.

    inv-04: Not supported / inferior evidence — scenarios where PRF is not supported or inferior

    Scenarios in which available trials do not support PRF or show inferiority to alternative treatments:

    Trigeminal neuralgia: At least one randomized, double‑blind trial found PRF ineffective compared with continuous RF thermocoagulation for idiopathic trigeminal neuralgia; systematic reviews concluded lower efficacy for PRF in this setting.

    PRF not supported as effective for trigeminal neuralgia in available RCT evidence.

    Sacro‑iliac joint (SIJ) pain: Systematic review concluded the evidence for PRF in SIJ pain is poor and does not support routine use.

    Evidence level rated poor.

    inv-05: Overall coverage summary — summary stance based on presented evidence

    Overall coverage stance based on the body of evidence summarized in this document:

    General coverage considerations: Across many indications the evidence for PRF is limited, heterogeneous, and frequently low quality; where evidence is poor or inconsistent, PRF should be considered investigational and its routine use outside well‑designed research or select cases after failed conservative therapy is not established.

    Based on multiple systematic reviews and summaries noting limited or poor evidence.

    inv-06: Conditional positive findings — selected condition-level findings

    Selected condition‑level findings from small RCTs or series that suggest potential benefit but are not definitive coverage criteria:

    Thoracic post‑herpetic neuralgia: A randomized double‑blind trial reported PRF reduced VAS and improved SF‑36 versus sham up to 6 months, but was limited by single‑center design and mid‑term follow‑up.

    Promising but not definitive.

    Chronic postsurgical thoracic pain (DRG PRF): Retrospective series reported higher ≥50% pain relief at 6 weeks and 3 months for DRG PRF versus medical management or intercostal PRF; prospective confirmation is needed.

    Preliminary positive outcomes reported.

    Inguinal neuralgia (DRG PRF): A small randomized double‑blind trial showed longer duration of pain relief versus sham, though sample size was small.

    Promising but limited evidence.

    inv-07: Evidence considerations — evidence summary and implications for coverage determination

    Key evidence considerations and implications for coverage determinations:

    General evidence considerations: Most supporting studies are small, observational, or single‑center with short follow‑up; a few RCTs exist with mixed results. Indications with promising signals (e.g., meralgia paresthetica, inter‑fascial PRF, C2 DRG for cervicogenic headache) require confirmation in larger, high‑quality RCTs before routine coverage can be recommended.

    Decisions should weigh study quality, comparator treatments, and reproducibility.

    inv-08: Evidence summaries by indication — evidence and conclusions for specific indications

    Evidence and conclusions reported in the document for specific indications (summarized):

    Cluster/Cervicogenic Headaches (SPG, C2 DRG): Small case series and prospective cohorts report symptom reductions; C2 DRG PRF showed responder rates in selected series but sample sizes were small and longer RCTs are needed.

    Authors call for larger RCTs.

    Abdominal cutaneous nerve entrapment syndrome (ACNES): Retrospective series reported 50% short‑term success at 6–8 weeks with median effect ~4 months; RCTs are underway.

    Small uncontrolled data.

    Ganglion Impar / Chronic Perineal Pain: A randomized double‑blind trial found conventional RF superior to PRF for ganglion impar over 6 weeks; PRF provided less durable relief in that study.

    Short follow‑up limits conclusions.

    Glossopharyngeal Neuralgia:

    inv-09: Coverage-relevant evidence summaries — limited, heterogeneous studies summarized

    Summarized, coverage‑relevant evidence across multiple reviews and trials (limited and heterogeneous):

    Peripheral post‑traumatic neuropathic pain: Single double‑blind RCT failed to show PRF superiority over sham for peripheral post‑traumatic neuropathic pain (no significant difference in primary outcome at 3 months); authors do not recommend PRF for this indication.

    Akural et al. RCT: inclusion pain ≥5 NRS and ≥6 months duration; prior temporary block required.

    Post‑surgical orchialgia: One prospective RCT reported greater pain reduction and decreased analgesic use with PRF vs sham at 3 months (80% vs 23% achieving >50% VAS reduction) but was limited by small sample and short follow‑up.

    Hetta et al. RCT: validation needed.

    Stump/post‑amputation pain: Case reports and small case series (including use of wearable noninvasive pulsed EMF devices) suggest possible benefit but evidence is preliminary and lacks randomized trials.

    Requires randomized evaluation.

    inv-10: Coverage-relevant clinical criteria (evidence-informed) — clinical use considerations drawn from evidence

    Evidence‑informed clinical considerations (not formal coverage criteria) that reflect the document’s conclusions:

    General criteria: Consider PRF only for indications that correspond to conditions discussed in the evidence base and primarily when conservative treatments have failed or are inadequate.

    Examples include refractory shoulder pain, zoster‑related pain, trigeminal PHN, lumbar radicular pain, chronic hip pain; use supported by case series/RCTs is variable.

    Evidence considerations: Prefer interventions with stronger comparative evidence when available (e.g., short‑term spinal cord stimulation showed superior pain reduction to PRF in some zoster‑related trials/meta‑analyses).

    stSCS superiority noted in meta‑analysis for zoster‑related pain.

    Adjunctive techniques: Consider PRF combined with adjunctive therapies (for example PRF plus dexamethasone for trigeminal PHN) where trial data show improved outcomes versus PRF alone.

    Single‑center RCT showed PRF+DEX superior to PRF alone for trigeminal PHN.

    Aetna considers pulsed radiofrequency (PRF) experimental and investigational for the enumerated indications because effectiveness has not been established. The policy lists 71 specific indications for which PRF is considered investigational, including but not limited to cervical radicular pain, occipital neuralgia, sacro‑iliac joint pain, peripheral post‑traumatic neuropathic pain, trigeminal neuralgia, post‑herpetic neuralgia, plantar fasciitis, and zoster‑related pain.

    PRF neurotomy/denervation procedures have been judged to have poor or limited evidence in some reviews of spinal injection therapies; moreover, certain external payer programs may not recognize PRF neurotomy as an established component of covered spinal injection services. Where local payer rules differ, PRF neurotomy may be excluded or denied based on those external program determinations.

    The document concludes there is insufficient evidence to support routine use of PRF for a variety of chronic pain syndromes. Across thoracic pain and other chronic pain conditions the literature is small, heterogeneous, and often limited to retrospective series; well‑designed randomized controlled trials with longer follow‑up are generally lacking.

    Although the Stimpod NMS460 received FDA clearance for symptomatic relief of chronic intractable pain, the policy notes insufficient evidence on the clinical value of this device in broader use. The bulletin does not provide explicit coverage‑exclusion language tied solely to device regulatory status, but it states that clinical effectiveness remains unestablished.

    Data for palmar hyperhidrosis are limited to preclinical (animal) studies; no human clinical evidence demonstrating efficacy of PRF for this indication is provided, and translation to clinical practice is unsupported by human data.

    A network meta‑analysis for plantar fasciitis found that ultrasound‑guided PRF (UG‑PRF) was not recommended and did not show stable, superior benefit compared with leading alternatives (for example, radial extracorporeal shock wave therapy). The review concluded UG‑PRF and high‑intensity focused shock wave were not endorsed as effective options in that analysis.

    Post‑arthroplasty patients may present anatomic distortion that makes identification of the neurovascular bundle difficult. When the anatomic target cannot be clearly identified (for example after total knee arthroplasty), study authors cautioned that PRF outcomes may be unreliable and procedures were performed only when the bundle could be clearly visualized.

    A systematic review and meta‑analysis of pulsed RF for chronic shoulder pain found no analgesic or functional benefit versus conventional medical management (GRADE: low). The lack of demonstrated benefit in shoulder pRF meta‑analysis suggests PRF should not be routinely expected to provide clinically meaningful improvement for shoulder indications without stronger supporting data.

    Consistent with the evidence summaries, use of pulsed radiofrequency for the listed indications and the specified unestablished modalities is considered not medically necessary / investigational when offered outside well‑designed clinical research or carefully selected protocols because effectiveness has not been established.

    For example, in the only prospective randomized double‑blind trial of PRF for idiopathic trigeminal neuralgia, PRF was found to be ineffective compared with continuous RF thermocoagulation; pain recurred by 3 months in the PRF group and investigators concluded PRF was ineffective for that indication.

    PRF neurotomy has been compared to other treatments (for example conventional RF neurotomy or intra‑articular steroid injections) in reviews of sacro‑iliac and other joint interventions, where PRF evidence was judged poor. Given the limited and low‑quality evidence, PRF neurotomy should be considered investigational relative to established approaches such as cooled RF neurotomy or other therapies with stronger evidence.

    Systematic reviews of cervicogenic and cluster headache interventions report very limited benefit from PRF approaches and note absence of high‑quality RCTs. Small case series and prospective cohorts have reported symptomatic improvements, but reviewers emphasize the need for larger, methodologically rigorous trials before routine use can be supported.

    Coding and Diagnosis Mapping

    Prior Authorization
    ICD-10 codes - not covered for indications listedICD-10Not Covered
    H93.11Tinnitus, subjective, right ear
    H93.12Tinnitus, subjective, left ear
    H93.13Tinnitus, subjective, bilateral
    H93.14Tinnitus, subjective, unspecified ear
    H93.15Tinnitus, objective, right ear
    H93.16Tinnitus, objective, left ear
    H93.17Tinnitus, objective, bilateral
    H93.18Tinnitus, objective, unspecified ear
    H93.19Tinnitus, other
    B02.21Zoster with other nervous system involvement
    1–10 of 69
    1/7
    Procedure coding noteCPT
    There are no specific CPT codes for pulsed radiofrequency; report using related radiofrequency/nerve destruction codes as clinically appropriate and per payer guidance.

    Provider Actions — Prior Authorization, Documentation, and Denial Risk

    Prior Authorization

    Prior authorization recommended for transcutaneous PRF (TCPRF)

    Controlled trials exist for transcutaneous PRF (TCPRF) in limited indications; when TCPRF or other limited‑evidence PRF modalities are requested, prior authorization is recommended so documented trial protocols and indication justification can be reviewed.

    Prior Authorization

    Prior authorization may be required due to insufficient evidence

    Because the evidence is insufficient for many PRF indications, prior authorization may be required when PRF is requested; documentation should demonstrate the clinical rationale and prior conservative care.

    Documentation Required

    Provide prior diagnostic block and conservative therapy documentation

    Submit documentation of prior diagnostic block response and trials of conservative therapy (medications, physical therapy, prior injections) and baseline pain/quality‑of‑life measures when requesting PRF for headache/cervicogenic or chronic pain indications.

    • Record degree of relief from diagnostic block (e.g., ≥50% relief where reported).
    • Provide pre‑procedure VAS/NRS and validated QOL scores and prior treatment history.
    Prior Authorization

    Prior authorization scrutiny for peripheral post‑traumatic neuropathic pain

    For peripheral post‑traumatic neuropathic pain, a randomized, double‑blind, sham‑controlled trial found no benefit of PRF over sham; requests for PRF in this indication should face heightened prior authorization scrutiny.

    Prior Authorization

    Prior authorization recommended for PRF because evidence quality is low

    Given low and variable quality of evidence across neuropathic and non‑neuropathic indications, prior authorization is appropriate when PRF is requested to ensure documentation of prior conservative therapies and rationale for the procedure.

    Prior Authorization

    Include evidence summary (RCTs/meta‑analyses) to justify prior authorization

    Cite randomized trials, systematic reviews, or meta‑analyses showing short‑term pain reductions and variable functional outcomes when justifying PRF in prior authorization requests.

    • Document relevant RCTs or meta-analyses and their reported outcomes (pain, function, follow‑up intervals).
    Prior Authorization

    Prior authorization for indications with limited or mixed evidence

    Consider prior authorization for PRF requests for indications with limited or mixed evidence (for example chronic shoulder pain, zoster‑related pain, trigeminal PHN) to ensure appropriate selection and alternative therapies were considered.

    • Highlight comparative evidence (e.g., stSCS vs PRF for zoster‑related pain) where relevant.
    Note

    No plan‑level prior authorization codes listed — check plan resources

    The bulletin does not list specific CPT/HCPCS codes that require prior authorization for PRF; providers should follow plan‑specific prior authorization resources and code lists.

    Step Therapy

    Studies often required prior failure of conservative measures before PRF

    Some cited studies required prior failure of conservative measures (diagnostic SIJ injections, physical therapy, repeat injections, analgesics) before PRF; prior authorization may require evidence of such trials.

    Documentation Required

    Document conservative therapies and diagnostic blocks before PRF

    Document prior conservative treatments (medications, injections, physical therapy) and diagnostic block results before PRF; studies frequently enrolled patients refractory to conventional therapy.

    • Indicate duration and outcomes of prior therapies and positive/temporary responses to diagnostic blocks.
    Step Therapy

    Expect conservative treatments before considering PRF

    Conservative treatments such as medications, injections, and physical therapy are generally expected prior to PRF given limited supporting evidence; include this history in authorization requests.

    Documentation Required

    Document failure of meds, PT, and prognostic blocks before PRF

    Evidence descriptions emphasize prior failure of medications, physical therapy, and prognostic blocks before PRF is used for conditions like coccydynia and meralgia paresthetica; document these failures.

    Step Therapy

    Try PVN PRF before thoracic DRG PRF; document step‑up approach

    For post‑mastectomy intercostobrachial neuralgia, trial data suggest attempting thoracic PVN PRF before thoracic DRG PRF because DRG targeting carries greater technical risk; document PVN failure before DRG PRF requests.

    • If DRG PRF is requested, include documentation that PVN PRF was attempted and failed or was not feasible.
    Step Therapy

    Document stepwise conservative management before PRF

    Many studies used PRF after failure of other treatments; prior authorization should require documentation of stepwise conservative management before approving PRF.

    Documentation Required

    Require prior conservative therapy and diagnostic medial branch block documentation

    Mid‑cervical medial branch PRF in studies was performed after failure of conservative care and positive diagnostic medial branch blocks; include prior block results and conservative care details in the record.

    Step Therapy

    Implied stepwise escalation: document prior therapies and surgical history

    PRF is commonly used after failure of conservative therapies and occasionally after surgery; prior authorization should verify prior noninvasive and more conservative interventions have been attempted.

    Note
    Documentation Required

    Provide supporting documentation of indication and prior conservative care

    Clinical documentation should support the indication and prior conservative therapies; many studies used diagnostic blocks and prior injections as selection criteria for PRF.

    • Include prior diagnostic block details, prior injections, and duration/outcomes of conservative therapy.
    Documentation Required

    Document positive diagnostic block response for occipital neuralgia

    Document a positive diagnostic nerve block response prior to PRF for occipital neuralgia when applicable, as used in prospective studies selecting patients for treatment.

    • Specify block agent, volume, and measured percent relief and duration.
    Documentation Required

    Include target, guidance method, and PRF parameters in procedure report

    Procedural reports should include the anatomic target, image‑guidance modality (fluoroscopy, CT, or ultrasound), and PRF parameters (voltage, temperature, pulse width, duration) when available.

    • Record guidance method and any sensory/motor stimulation thresholds used.
    • Include PRF settings (e.g., 42°C for 120 seconds where reported) and number of applications.
    Documentation Required

    Record prior block response and baseline/follow‑up pain and QOL measures

    Required clinical documentation for PRF requests includes prior diagnostic block response, pre‑ and post‑procedure pain and QOL measures, and follow‑up outcomes to support effectiveness claims.

    • Pre‑procedure VAS/NRS and validated QOL scores (e.g., SF‑36, SPADI) and post‑procedure follow‑up values.
    • Degree of relief from diagnostic blocks (percent) and duration of symptoms.
    Documentation Required

    Use and document baseline/follow‑up scores and responder definitions (≥30% or ≥50%)

    Document baseline and follow‑up pain scores and use common responder definitions (studies commonly used ≥30% or ≥50% pain reduction) when reporting outcomes after PRF.

    • State responder threshold applied (e.g., ≥50% reduction in VAS) and time‑points of measurement.
    Documentation Required

    Include indication, prior therapies, and diagnostic block responses in documentation

    Include indication, prior conservative treatments, and diagnostic block responses in the prior authorization package; studies routinely required these elements for patient selection.

    Documentation Required

    Document trial endpoints (VAS, SPADI, SF‑36) and adverse events

    Outcome measurement documentation from trials includes VAS, SPADI, SF‑36 and adverse events; include these measures at specified time‑points when available to support clinical benefit.

    Documentation Required

    Recommended documentation: indication, prior measures, diagnostic blocks, and outcome scores

    Clinical documentation supporting PRF requests should include the specific indication, prior conservative measures tried, diagnostic block details, and baseline and follow‑up outcome scores.

    • List prior surgeries or interventions and their outcomes when relevant (e.g., prior TKA for genicular PRF).
    Note

    Follow plan‑specific documentation and prior authorization processes

    This policy bulletin is informational and partial; follow plan‑specific documentation and prior authorization processes because the bulletin does not specify all plan requirements.

    Denial Risk

    Denial risk for indications listed as experimental/investigational

    Procedures for indications listed as experimental and investigational are subject to denial because effectiveness has not been established for those indications.

    Denial Risk

    Evidence quality concerns may trigger denial of coverage

    High or medium risk of bias and generally poor study quality reported in reviews may lead payers to deny coverage when evidence of efficacy is insufficient for the specific indication.

    Denial Risk

    Insufficient evidence may lead to noncoverage outside research settings

    Insufficient evidence for many chronic pain syndromes means PRF offered outside well‑designed research protocols may be denied or considered noncovered.

    Denial Risk

    No prior diagnostic block response increases risk of non‑response and denial

    Lack of a prior diagnostic block response is associated with lower likelihood of PRF success (for example, C2 DRG PRF success was linked to prior ≥50% relief from a C2 DRG block); absence of such a response may increase denial risk.

    Denial Risk

    Negative RCT for peripheral post‑traumatic neuropathic pain increases denial risk

    A double‑blind, sham‑controlled RCT failed to show efficacy of PRF over sham for peripheral post‑traumatic neuropathic pain; that high‑quality negative trial may be used as a basis for denial in this indication.

    Denial Risk

    Denial risk due to low‑quality or preliminary evidence

    Because the overall evidence is low and preliminary for many PRF applications, payers may deny coverage when high‑quality randomized evidence is lacking or when PRF is used without comparative data.

    Denial Risk

    Anatomic target identification issues may affect coverage

    When anatomic targets cannot be clearly identified (for example post‑arthroplasty distortion of the neurovascular bundle), appropriateness of PRF is affected and this may lead to noncoverage.

    Denial Risk

    Evidence limitations for shoulder PRF may prompt denials

    Limited or negative evidence for shoulder PRF (meta‑analysis showing no analgesic or functional benefit) could prompt denials for shoulder indications absent stronger supporting documentation.

    Note

    Policy bulletin is partial — verify member benefits and prior authorization rules

    Clinical Policy Bulletins are informational and partial; coverage and denial decisions depend on plan terms, so providers must verify benefits and follow prior authorization processes.

    Conservative Treatment Requirements Before PRF

    inv-79: Prior conservative management or diagnostic injections commonly used in cited literature before PRF

    Document prior conservative therapies and diagnostic/prognostic blocks as typically required by cited studies before PRF is considered:

    Prior conservative management required: Document failure of appropriate conservative management (for example: optimized medications, physical therapy, targeted injections) prior to PRF consideration.

    Multiple studies and reviews selected patients refractory to conservative therapy; see cited literature.

    Diagnostic/prognostic nerve block when applicable: Where applicable to the target (e.g., occipital neuralgia, meralgia paresthetica, peripheral nerve targets, C2 DRG), document a positive diagnostic nerve block (commonly temporary ≥50% pain relief) prior to PRF.

    Several prospective studies used diagnostic block response for patient selection.

    Duration expectation for chronic neuropathic pain trials: For chronic neuropathic pain indications included in RCTs, symptoms were commonly present ≥6 months before enrollment; document duration and prior failed therapies (many trials required ≥6 months).

    Documented inadequate response commonly ≥6 months in some RCTs.

    Procedural documentation: Provide procedural details including target nerve/DRG, imaging guidance modality, PRF parameters (temperature, duration, pulse width) and pre/post pain scores to support outcome assessment.

    Many studies reported detailed procedural parameters and outcome measures.

    inv-80: Document failure of conservative therapies and, where applicable, a positive diagnostic nerve block prior to PRF.

    Document failure of conservative therapies and, when applicable, a positive diagnostic nerve block prior to PRF.

    Conservative therapy failure documented: Clinical record must document failure of appropriate conservative therapies (e.g., medications, physical therapy, targeted injections) prior to PRF.

    Case series and trials commonly enrolled patients refractory to previous management.

    Positive diagnostic block when used: When the evidence or study protocols used diagnostic blocks for patient selection (for example occipital nerve block for occipital neuralgia), document prior positive diagnostic local anesthetic block response (often defined as temporary ≥50% relief).

    Prospective occipital PRF studies required a positive test block.

    inv-81: Failure of appropriate conservative management (meds, PT, diagnostic blocks) expected before PRF is considered.

    Failure of appropriate conservative management (medications, physical therapy, diagnostic blocks) is expected before PRF is considered.

    Expectation of prior conservative care: Most studies evaluated PRF after failure of other therapies; document trials of medications, injections, and physical therapy prior to PRF.

    Systematic reviews and series emphasize selection of refractory patients.

    inv-82: Documentation of failed conservative treatments and/or positive diagnostic/prognostic block response is appropriate prior to PRF.

    Documentation of failed conservative treatments and/or positive diagnostic/prognostic block response is appropriate prior to PRF.

    Document failed conservative treatments: Clinical documentation should list prior conservative treatment attempts and their outcomes (medications, physical therapy, injections) before proceeding to PRF.

    Multiple reports describe PRF after failure of conservative therapies.

    Document diagnostic/prognostic block response: When prognostic or diagnostic nerve blocks were used in the literature to select patients (e.g., LFCN block for meralgia paresthetica, C2 DRG block for CEH), document the block technique and degree/duration of pain relief.

    Positive block response was associated with better outcomes in some series.

    inv-83: Documented inadequate response to conservative therapy and, when applicable, diagnostic nerve block prior to PRF (commonly ≥6 months in some RCTs).

    Documented inadequate response to conservative therapy and, when applicable, diagnostic nerve block prior to PRF (trial durations in RCTs commonly ≥6 months).

    Inadequate response duration: For chronic neuropathic pain indications enrolled in RCTs, symptoms and prior failed conservative management were commonly present for ≥6 months; document symptom duration and prior therapies.>= 6 months

    Some RCTs required ≥6 months of symptoms prior to enrollment.

    Diagnostic block documentation: Where trials used diagnostic blocks as selection criteria (e.g., occipital neuralgia, C2 DRG), document the block result (percent relief, duration) in the medical record.

    Positive prognostic block predicted better outcomes in some studies.

    inv-84: Document prior conservative treatments and failed interventions prior to PRF; diagnostic blocks commonly used for selection.

    Document prior conservative treatments and failed interventions prior to PRF; diagnostic blocks commonly used for selection.

    Prior treatments list: Provide a history of prior conservative and invasive therapies attempted and their outcomes (medications, PT, injections, prior surgeries) before PRF.

    Most studies enrolled patients after other therapies failed.

    Diagnostic block when applicable: Document whether diagnostic or prognostic nerve/DRG blocks were performed and the magnitude/duration of relief to support candidacy for PRF.

    DRG‑targeted PRF studies typically initiated PRF after other treatments failed.

    inv-85: Document prior conservative treatment attempts and prior diagnostic or therapeutic blocks when applicable.

    Document prior conservative treatment attempts and prior diagnostic or therapeutic blocks when applicable.

    Cervicogenic headache example: For mid‑cervical medial branch PRF, documentation typically included prior conservative care, response to medial branch blocks (performed twice), and persistent pain before PRF.

    Studies applied PRF after failure of conservative management and diagnostic blocks.

    inv-86: Document prior conservative treatments and their failure before PRF for chronic refractory pain indications.

    Document prior conservative treatments and their failure before PRF for chronic refractory pain indications.

    Chronic refractory pain documentation: For chronic refractory conditions (e.g., chronic shoulder or hip pain), document prior noninvasive and invasive therapies (analgesics, injections, physical therapy, and prior surgery if applicable) and their lack of durable benefit prior to PRF.

    Case reports and series commonly used PRF after other treatments failed.

    Frequency Limits and Repeat Treatment

    PRF applications — repeat treatments and effectiveness
    Summary of repeat treatmentsRepeat PRF treatments reported with variable intervals across studies; effectiveness duration commonly ranged from about 2 to 12 months depending on indication and study.
    Reported duration of effect (example)In lumbosacral spondylosis case series effective duration ranged 5–18 months (mean ~9 months); DRG administrations effective 2–12 months (mean ~7 months).
    Clinical implicationRepeat treatments may be required as benefit wanes; intervals and retreatment timing were heterogeneous in the literature.
    Repeats of intra-articular PRF
    Observed repeat scheduleIn an intra-articular PRF series (n=57), the procedure was repeated after 1 month in 10 patients with initial suboptimal results.
    No formal frequency limitAuthors did not specify a formal or universal frequency limit for repeating intra-articular PRF in the report.
    Outcome after repeatRepeated IA PRF produced successful ≥50% pain reduction in many cases, including some patients with prior prosthetic joint replacement.
    DRG PRF for inguinal neuralgia — retreatment allowed
    Study retreatment ruleIn a randomized trial of DRG PRF for inguinal neuralgia, repeated PRF blockade was allowed for any patient reporting VAS > 30 mm during the 1-year follow-up.
    Number of blocks reportedSome patients received up to 3 blocks during the 1-year follow-up in the study protocol; most required two blocks while a few needed a third.
    Effect on durationSecond PRF produced prolonged pain relief (reported out to months) with variable durations between groups in that trial.
    No explicit frequency limits in cited segments
    Absence of explicit limitsMultiple background sections and device discussion do not provide explicit, universal frequency limits for PRF procedures.
    Frequency left to protocol/clinical judgmentRetreatment timing and number were dictated by individual study protocols or clinician judgment rather than a standardized policy limit.
    Documentation implicationBecause no universal frequency limit is specified, clinical documentation should justify repeat procedures and describe prior benefit and timing.
    PRF procedures — examples of multiple closely spaced treatments
    Variable repeat intervals reportedIn a PMPS series (100 patients) PRF plus steroid was repeated three times, 1 week apart for each patient as part of the protocol.
    Protocol-driven schedulesSome protocols applied multiple PRF sessions at short intervals (example: three weekly treatments) depending on indication and combination therapy.
    No universal standardThese reports show heterogenous practice patterns with no single consensus interval for repeat PRF treatments.
    No explicit frequency limits in other document segments
    Lack of frequency limits in other segmentsRandomized trials and systematic reviews (e.g., UG-PRF frozen shoulder RCT, knee OA RFA analyses) do not establish standardized retreatment frequency limits for PRF.
    Study-specific practicesIndividual RCTs described treatment regimens and follow-up but did not prescribe generalized frequency caps applicable across indications.
    Implication for payers/providersRetreatment decisions should be supported by procedural documentation, prior response, and study-based rationale when available.

    Imaging and Guidance for PRF Procedures

    Documentation Required

    Fluoroscopy commonly used for PRF procedures

    Fluoroscopy is commonly used for PRF procedures and is described in background as the typical imaging modality for needle placement.

    Note
    Documentation Required

    Use CT/fluoroscopy/ultrasound as appropriate to the target and document it

    PRF procedures targeting various nerves or joints have been performed with CT, fluoroscopy, or ultrasound as appropriate to the anatomic target; document the imaging modality used.

    • Use the imaging modality appropriate to the target (CT for foramen ovale/Gasserian ganglion, US for peripheral nerves, fluoroscopy for spinal/DRG targets).
    Documentation Required

    C2 DRG and similar procedures: fluoroscopy or ultrasound as clinically appropriate

    For C2 DRG and other cervical procedures, fluoroscopy or ultrasound guidance is reported as clinically appropriate; include guidance modality in procedural documentation.

    Note
    Note
    Documentation Required

    Image guidance commonly required for DRG, peripheral nerve, ganglion, and genicular PRF

    Image guidance (fluoroscopy or ultrasound) is commonly necessary and should be used/documented when targeting DRG, peripheral nerves, ganglion impar, supraorbital nerve, or genicular nerves.

    • Document target localization method (US or fluoroscopy) and any stimulation testing performed.
    Note

    Definitions and Terminology

    Pulsed radiofrequency (PRF) — definition
    Concise definitionPulsed radiofrequency (PRF) is a minimally neurodestructive technique that delivers short bursts of radiofrequency energy to nervous tissue (also called cold RF).
    Mechanism and intentPRF uses pulsed time cycles so the needle remains relatively cool between bursts, reducing the risk of destroying nearby tissue compared with continuous RF.
    Typical guidancePRF treatments are typically performed under fluoroscopic guidance as described in background reports.
    Pulsed radiofrequency — alternate description
    Alternate phrasingPRF delivers short bursts of RF energy to neural structures at settings intended to avoid neurodestructive temperatures, postulated to exert neuromodulatory effects via non-thermal mechanisms.
    Clinical uncertaintyClinical advantages and mechanisms remain unclear and further research is justified per reviews.
    Safety noteReports to date noted few procedure-related complications in many series, but overall evidence quality is limited.
    Dorsal root ganglion (DRG) PRF
    DRG PRF definitionDorsal root ganglion (DRG) PRF refers to application of PRF adjacent to the dorsal root ganglia to treat radicular or neuropathic pain.
    Evidence contextDRG-targeted PRF has been studied for lumbar, cervical, and thoracic radicular pain with predominantly small studies and low-quality evidence.
    Study characteristicsSystematic reviews of DRG PRF include many small non-randomized studies; only a few RCTs are available and findings are preliminary.
    Short-term pain relief — definition
    Short-term relief timeframeShort-term pain relief is defined in systematic review assessments as relief lasting up to 6 months.
    Use in evidence appraisalThis short-term window is used as a primary outcome interval in SIJ and other reviews assessing PRF efficacy.
    Clinical implicationMany PRF reports document outcomes within weeks to months consistent with the short-term definition.
    Long-term pain relief — definition
    Long-term relief timeframeLong-term pain relief is defined as pain relief lasting greater than 6 months in systematic review assessments.
    Evidence gapMany studies have limited follow-up and do not reliably demonstrate long-term (>6 months) benefit for PRF across indications.
    Research needLarger, longer RCTs are needed to establish durability of PRF beyond the long-term threshold.
    Device — Stimpod NMS460
    Device descriptionStimpod NMS460 is a non-invasive transcutaneous neuromodulation device that applies a proprietary hybrid RF waveform transcutaneously and includes nerve-locating technology.
    Regulatory noteThe Stimpod NMS460 received FDA clearance (January 18, 2017) for symptomatic relief and management of chronic intractable pain and related adjunctive uses.
    Evidence limitationDespite FDA clearance, the document states there is insufficient evidence on the clinical value of the Stimpod NMS460 for broader clinical use.
    Responder definitions used in studies
    Responder thresholds used in studiesResponder definitions in cited studies commonly used ≥30% or ≥50% reductions in pain (NRS/VAS or weekly attack frequency) depending on study and indication.
    Outcome reportingStudies reported responder rates at specified follow-up intervals (e.g., ≥30% reduction for cluster attacks, ≥50% VAS reduction for other trials).
    Documentation expectationClinical documentation for prior authorization should include baseline and follow-up pain scores to assess responder status per these thresholds.
    PRF — general definition
    General PRF definitionPRF is a non-destructive radiofrequency technique that delivers pulsed electromagnetic fields to neural structures intended to modulate neurocellular function with minimal tissue destruction.
    Application targetsPRF has been applied to peripheral nerves, DRG, sympathetic chain, and ganglia in various clinical reports.
    Mechanistic uncertaintyLaboratory reports suggest neuromodulatory neurobiological effects but mechanisms are not fully elucidated.
    Pudendal neuralgia (PN) — definition
    Pudendal neuralgia definitionPudendal neuralgia (PN) involves severe, sharp or burning pain along the course of the pudendal nerve, often aggravated by sitting and refractory to conservative measures.
    Clinical coursePN is difficult to treat and may require diagnostic blocks and multiple treatments; PRF has been reported in case reports/series with some prolonged benefit.
    Evidence statusReports are limited and PRF for PN remains investigational pending higher-quality studies.
    RF modality distinctions
    Modality distinctionsRF modality distinctions include bipolar versus monopolar electrode configurations and modality types (cooled, conventional, pulsed), which affect temperature, lesion characteristics, and reported efficacy.
    Comparative findingsNetwork meta-analysis found bipolar techniques often outperformed monopolar in some outcomes; cooled modalities showed greater short-term benefit than pulsed in knee OA analyses.
    Clinical relevanceModality and electrode configuration choice may influence outcomes and should be considered when interpreting PRF trial results.
    UG-PRF — ultrasound-guided PRF
    UG-PRF definitionUltrasound-guided PRF (UG-PRF) refers to PRF procedures performed using ultrasound imaging for needle guidance and target localization.
    Use in trialsUG-PRF was used in RCTs (e.g., frozen shoulder) and multiple observational studies; authors recommend further validation and longer follow-up.
    Guidance advantageUltrasound guidance can minimize radiation exposure and assist in precise peripheral nerve targeting.
    PRF (pulsed radiofrequency) — concise definition
    Concise PRF phrasePulsed radiofrequency (PRF) — a minimally neurodestructive pulsed application of radiofrequency that delivers short bursts of energy to neural tissue to reduce tissue destruction compared with continuous RF.
    SynonymsAlso referred to as cold RF or pulsed RFT in the literature.
    Typical procedural contextOften used as an alternative to conventional RF neurotomy in palliative chronic pain management.
    stSCS (short-term spinal cord stimulation) — definition and context
    stSCS definitionShort-term spinal cord stimulation (stSCS) is a temporary spinal cord stimulation intervention used for zoster-related pain and as a comparator in trials.
    Comparative evidenceMeta-analyses suggest stSCS may provide greater pain reduction and improved outcomes compared with PRF in some zoster-related trials.
    ImplicationWhere stSCS evidence is stronger, it may be preferred over PRF for select zoster-related indications based on trial data.

    Not Covered / Exclusions (Documented Items)

    All indications and listed modalities identified in the policy are considered not covered / investigational in routine practice. Providers requesting PRF for any of the enumerated conditions should be aware that those uses are deemed investigational and therefore subject to non‑coverage or denial unless presented as part of approved research or supported by strong, plan‑specific justification.

    PRF for idiopathic trigeminal neuralgia is specifically referenced as not covered when RCT evidence demonstrates inferiority to continuous RF; the randomized trial cited showed PRF to be ineffective versus continuous RF thermocoagulation.

    Routine use of PRF for many chronic pain syndromes is not supported by the available evidence. Systematic reviews and summary analyses repeatedly describe the evidence as poor, heterogeneous, or insufficient to establish clinical benefit, supporting a not‑covered stance for routine application.

    The trial showing PRF inferior to continuous RF in trigeminal neuralgia is referenced multiple times in the evidence summaries and is an explicit example of an indication where PRF is not supported by randomized comparative data.

    Duplicate placeholders referencing the trigeminal neuralgia trial reiterate that where RCT data demonstrate inferiority of PRF to established alternatives, PRF is considered not covered for that indication.

    Additional duplicate placeholders emphasize the policy position that the enumerated investigational indications and specified modalities are not covered in routine practice.

    Further duplicate entries reiterate that PRF uses listed in the policy are investigational and not covered absent compelling, plan‑specific evidence.

    These repeated not‑covered placeholders reflect the policy's comprehensive enumeration of investigational PRF indications and modalities.

    The policy's list of investigational indications and modalities is extensive; the repeated not‑covered placeholders flag multiple entries from that list as outside routine coverage.

    Additional not‑covered placeholders correspond to individual items in the enumerated list and reiterate the investigational status across indications.

    Background and Evidence Context

    Radiofrequency procedures are minimally invasive interventions used for chronic pain management. Pulsed radiofrequency (PRF) is a non‑ablative variant that delivers short bursts of radiofrequency energy intended to neuromodulate neural structures while avoiding the tissue temperatures associated with continuous (ablative) RF. The evidence base for PRF is dominated by case series and small trials with limited long‑term follow‑up, and reported benefits are often short‑term and variable across indications.

    Policy Summary
    PayerAetna
    PolicyPulsed Radiofrequency
    Policy CodePolicy 0735
    Change TypeNo material change
    Effective DateAug 21, 2007
    Last ReviewSep 20, 2023
    Next Review DateAug 8, 2024
    Key ActionObtain prior authorization and document failure of conservative therapies and diagnostic block responses when requesting pulsed radiofrequency.
    SourceLink
    On This Page
    Coverage Criteria — Pulsed RadiofrequencyCoding and Diagnosis MappingProvider Actions — Prior Authorization, Documentation, and Denial RiskConservative Treatment Requirements Before PRFFrequency Limits and Repeat TreatmentImaging and Guidance for PRF ProceduresDefinitions and TerminologyNot Covered / Exclusions (Documented Items)Background and Evidence Context

    Placebo‑controlled RCTs are generally lacking for these indications.

    Prospective interventional trial in oropharyngeal carcinoma reported high response rates (92% effective >3 months) with mean relief 5–9 months; multicenter RCTs needed.

    Promising single‑center data.

    Hemiplegic Shoulder Pain after Stroke: Small case series reported improvements in pain and function at 4 and 16 weeks; underpowered and uncontrolled.

    Larger RCTs needed.

    Idiopathic Axonal Polyneuropathy / Caudal Epidural PRF: Prospective series (n=20) reported significant NRS reductions and 50% responders at 3 months; small size and limited follow‑up.

    Preliminary evidence.

    Supraorbital Neuralgia: Prospective series (n=22) reported effectiveness rates of 77% at 1–3 months and 50% at 2 years after single PRF; needs validation.

    Preliminary findings.

    Intercostobrachial Neuralgia / PMPS: Multiple studies including an RCT (n=64) showed PRF to thoracic DRG and PVN reduced pain; DRG PRF provided better longer‑term analgesia but is technically riskier; combination with steroid reported in series with improvement to 6 months.

    Further confirmation desirable.

    Palmar Hyperhidrosis: Evidence limited to animal data; no human clinical evidence provided.

    Not translatable without human studies.

    Peripheral Neuralgia / Peripheral Nerve PRF: Retrospective review reported 80% of patients improved with mean duration ~129 days; authors call for larger trials.

    Low‑quality evidence.

    Peripheral Post‑Traumatic Neuropathic Pain: A double‑blind, sham‑controlled RCT (n=45 randomized, 43 analyzed) found no significant difference between PRF and sham at 3 months; investigators do not recommend PRF for this indication based on that trial.

    High‑quality negative trial for this indication.

    Sural neuralgia, plantar fasciitis, pudendal neuralgia, genicular PRF: Small series and meta‑analyses report mixed or preliminary benefits (e.g., UG‑PRF not recommended for plantar fasciitis by one network meta‑analysis); overall evidence is low quality.

    Larger RCTs needed.

    General evidence quality: Systematic reviews repeatedly conclude overall evidence for PRF is low or very low with few RCTs and predominant high/unclear risk of bias; findings are preliminary.

    Vuka et al. reviews and others summarize small heterogeneous studies.